Results 201 to 210 of about 73,286 (248)
Some of the next articles are maybe not open access.
Biofilms and vulvovaginal candidiasis
Colloids and Surfaces B: Biointerfaces, 2019Candida species, including C. albicans, are part of the mucosal flora of most healthy women, and inhabit the gastrointestinal and genitourinary tracts. Under favourable conditions, they can colonize the vulvovaginal mucosa, giving rise to symptomatic vulvovaginal candidiasis (VVC). The mechanism by which Candida spp.
Rodríguez-Cerdeira, Carmen +9 more
openaire +3 more sources
New Antifungals for Vulvovaginal Candidiasis: What is their role?
Clinical Infectious Diseases, 2023New antifungals, Ibrexafungerp and Oteseconazole are recently available for treatment of vulvovaginal candidiasis. Both have novel antimicrobial and pharmacokinetic properties with advantages over fluconazole, although comparative trials only involved ...
J. Sobel
semanticscholar +1 more source
Current Medicinal Chemistry, 2023
Oteseconazole was approved by the US FDA in April 2022. It is the first approved selective and orally bioavailable CYP51 inhibitor for the treatment of patients with recurrent Vulvovaginal candidiasis.
S. De
semanticscholar +1 more source
Oteseconazole was approved by the US FDA in April 2022. It is the first approved selective and orally bioavailable CYP51 inhibitor for the treatment of patients with recurrent Vulvovaginal candidiasis.
S. De
semanticscholar +1 more source
Vulvovaginal Candidiasis-An Overview of Current Trends and the Latest Treatment Strategies.
Microbial PathogenesisVulvovaginal candidiasis (VVC) is becoming more common, mostly affecting hospitalized and immunocompromised people. Candida albicans, among other species, is a significant causal agent, accounting for 90% of infections.
VASUNDHARA B BHOSALE +2 more
semanticscholar +1 more source
Epidemiology of Vulvovaginal Candidiasis in Greece: A 2‐Year Single‐Centre Study
Mycoses (Berlin)The epidemiology of vulvovaginal candidiasis (VVC) in Greece remains poorly reported and outdated.
Vasiliki Kroustali +5 more
semanticscholar +1 more source
Ibrexafungerp in the Treatment of Vulvovaginal Candidiasis
Annals of Pharmacotherapy, 2022Objective To review the pharmacology, efficacy, and safety of ibrexafungerp in the management of vulvovaginal candidiasis (VVC). Data Sources Literature was sought using PubMed (1966—February 2022) and EMBASE (1973—February 2022), and ...
Kylie N. Barnes +2 more
openaire +2 more sources
Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis: A Drug Review
The Annals of Pharmacotherapy, 2023Objective: The objective of the study is to describe and analyze the pharmacodynamics and pharmacokinetics of oteseconazole as well as the clinical evidence supporting the efficacy of oteseconazole in treating recurrent vulvovaginal candidiasis (RVVC ...
Cameron G. Lanier, Tyler C. Melton
semanticscholar +1 more source
Recurrent Vulvovaginal Candidiasis
New England Journal of Medicine, 1986Recurrent vulvovaginal candidiasis (RVVC) is a common cause of significant morbidity in women in all strata of society affecting millions of women worldwide. Previously, RVVC occurrence was limited by onset of menopause but the widespread use of hormone replacement therapy has extended the at-risk period.
openaire +2 more sources
Chronic Vulvovaginal Candidiasis
New England Journal of Medicine, 2004Vulvovaginal symptoms are common, and they represent one of the most frequent reasons for visits to physicians by women in all age groups. Vulvovaginitis is rarely life-threatening, and it is therefore vastly understudied and poorly understood. However, it is associated with substantial, albeit poorly quantified, cumulative morbidity. It causes genital
openaire +2 more sources
Future Microbiology, 2023
Aim: This study investigated the inhibition of extract of Sophorae flavescentis radix-Cnidii fructus couplet medicines (ESCC) on Candida albicans (C. albicans) in vitro and the effect of ESCC on the vaginal mucosal barrier in vivo.
Haitao Zhang +4 more
semanticscholar +1 more source
Aim: This study investigated the inhibition of extract of Sophorae flavescentis radix-Cnidii fructus couplet medicines (ESCC) on Candida albicans (C. albicans) in vitro and the effect of ESCC on the vaginal mucosal barrier in vivo.
Haitao Zhang +4 more
semanticscholar +1 more source